Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days

Transplantation

Volumn 90, Issue 12, 2010, Pages 1414-1419

  Welker, Horst ^a   Farhan, Mahdi ^b   Humar, Atul ^c   Washington, Carla ^d  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ROCHE PRODUCTS LTD   (United Kingdom)

^c UNIVERSITY OF ALBERTA   (Canada)

^d GENENTECH INC   (United States)

Author keywords

CMV; Ganciclovir; Kidney transplant; Pharmacokinetics; Valganciclovir

Indexed keywords

GANCICLOVIR; PLACEBO; VALGANCICLOVIR;

ADOLESCENT; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CREATININE CLEARANCE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; FEMALE; GRAFT RECIPIENT; HUMAN; INCIDENCE; KIDNEY GRAFT; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NEUTROPENIA; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; AREA UNDER CURVE; CREATININE; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROBABILITY; TIME FACTORS;

EID: 78650812839     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182000042     Document Type: Article

References (15)

1. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601.
2. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solidorgan transplants: A systematic review of randomised controlled trials. Lancet 2005; 365: 2105.
3. Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870.
4. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. In- ternational Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 1462.
5. Doyle AM, Warburton KM, Goral S, et al. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 2006; 81: 1106.
6. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779.
7. Schnitzler MA, Lowell JA, Hmiel SP, et al. Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: The importance of HLA-DR matching. J Am Soc Nephrol 2003; 14: 780.
8. Valentine VG, Weill D, Gupta MR, et al. Ganciclovir for cytomegalovirus: A call for indefinite prophylaxis in lung transplantation. J Heart Lung Transplant 2008; 27: 875.
9. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 2811.
10. Asberg A, Rollag H, Hartmann A. Valganciclovir for the prevention and treatment ofCMVin solid organ transplant recipients. Expert Opin Pharmacother 2010; 11: 1159.
11. Razonable RR, Paya CV. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. Expert Rev Anti Infect Ther 2004; 2: 27.
12. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228.
13. Wiltshire H, Hirankarn S, Farrell C, et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005; 44: 495.
14. Beal S, Sheiner L.NONMEMUser's Guide,NONMEMProject Group: University of California, San Francisco. 1992.
15. Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005; 79: 1477.